- Home
- STTK vs USEG Comparison
STTK vs USEG Comparison
Compare STTK & USEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- USEG
- Stock Information
- Founded
- STTK 2016
- USEG 1966
- Country
- STTK United States
- USEG United States
- Employees
- STTK N/A
- USEG N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- USEG Oil & Gas Production
- Sector
- STTK Health Care
- USEG Energy
- Exchange
- STTK Nasdaq
- USEG Nasdaq
- Market Cap
- STTK 37.6M
- USEG 40.1M
- IPO Year
- STTK 2020
- USEG N/A
- Fundamental
- Price
- STTK $0.91
- USEG $1.22
- Analyst Decision
- STTK Hold
- USEG Strong Buy
- Analyst Count
- STTK 4
- USEG 2
- Target Price
- STTK $3.00
- USEG $2.75
- AVG Volume (30 Days)
- STTK 108.4K
- USEG 168.1K
- Earning Date
- STTK 05-01-2025
- USEG 05-12-2025
- Dividend Yield
- STTK N/A
- USEG N/A
- EPS Growth
- STTK N/A
- USEG N/A
- EPS
- STTK N/A
- USEG N/A
- Revenue
- STTK $4,606,000.00
- USEG $16,145,000.00
- Revenue This Year
- STTK N/A
- USEG $23.82
- Revenue Next Year
- STTK N/A
- USEG N/A
- P/E Ratio
- STTK N/A
- USEG N/A
- Revenue Growth
- STTK 69.65
- USEG N/A
- 52 Week Low
- STTK $0.69
- USEG $0.81
- 52 Week High
- STTK $11.76
- USEG $6.40
- Technical
- Relative Strength Index (RSI)
- STTK 47.64
- USEG 55.75
- Support Level
- STTK $0.84
- USEG $1.08
- Resistance Level
- STTK $1.00
- USEG $1.19
- Average True Range (ATR)
- STTK 0.09
- USEG 0.06
- MACD
- STTK 0.01
- USEG 0.02
- Stochastic Oscillator
- STTK 42.02
- USEG 88.24
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About USEG U.S. Energy Corp. (DE)
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.